NASDAQ
Total Transactions
10
3 buys /7 sells
Shares Acquired
15,000
Transactions: 3•Avg: 5,000
Shares Disposed
30,000
Transactions: 7•Avg: 4,285.71
Net Activity
-15,000
Net Selling•Ratio: 42.86%
Q4 2025(Current) | 15,000 | 30,000 | -15,000 | 42.86% |
Q3 2025 | 45,000 | 106,492 | -61,492 | 37.50% |
Q2 2025 | 380,590 | 357,323 | +23,267 | 360.00% |
Q1 2025 | 980,500 | 75,285 | +905,215 | 107.69% |
Q4 2024 | 16,706 | 41,582 | -24,876 | 40.00% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q4 2025
Acquired vs Disposed Shares
Net Distribution: 15,000 shares•Acquired/Disposed Ratio: 42.86%
Net Activity | |||||
|---|---|---|---|---|---|
SRS Struthers Richard Scott | Director, officer: president & ceo | 10 | 573,670 | 203,008 | +370,662 |
ST Schilke Tobin | Officer: chief financial officer | 3 | 132,000 | 0 | +132,000 |
KI Kalofonos Isabel | Officer: chief commercial officer | 2 | 100,000 | 0 | +100,000 |
KJE Knight Jeff E. | Officer: chief operating officer | 12 | 134,073 | 60,736 | +73,337 |
WM Wilson Marc | Unknown | 8 | 69,056 | 88,112 | -19,056 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2025-12-01 | Officer: chief med and dev officer | Purchase | 5,000 | $16.89 | $84,450 | 71,837 | |
2025-12-01 | Officer: chief med and dev officer | Sale | 5,000 | $16.89 | $84,450 | 69,042 | |
2025-12-01 | Officer: chief med and dev officer | Sale | 5,000 | $45.02 | $225,100 | 66,837 | |
2025-11-03 | Officer: chief med and dev officer | Sale | 5,000 | $16.89 | $84,450 | 74,042 | |
2025-11-03 | Officer: chief med and dev officer | Purchase | 5,000 | $16.89 | $84,450 | 71,270 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
PD Pizzuti Dana | Officer: chief med and dev officer | Dec 3, 2025 | |
PD Pizzuti Dana | Officer: chief med and dev officer | Dec 3, 2025 | |
PD Pizzuti Dana | Officer: chief med and dev officer | Dec 3, 2025 | |
PD Pizzuti Dana | Officer: chief med and dev officer | Nov 5, 2025 | |
PD Pizzuti Dana | Officer: chief med and dev officer | Nov 5, 2025 |
Net change in shares shown on right
No price data available for this timeframe.